蚌埠医学院学报
蚌埠醫學院學報
방부의학원학보
ACTA ACADEMIAE MEDICINAE BENGBU
2014年
10期
1333-1335,1336
,共4页
袁媛%范宏娟%于增荣%施慧
袁媛%範宏娟%于增榮%施慧
원원%범굉연%우증영%시혜
乳腺肿瘤%血管内皮生长因子%免疫组织化学%荧光原位杂交%分子分型
乳腺腫瘤%血管內皮生長因子%免疫組織化學%熒光原位雜交%分子分型
유선종류%혈관내피생장인자%면역조직화학%형광원위잡교%분자분형
breast neoplasms%vascuoar endothelial growth factor%immunohistochemical%fluorescence in situ hybridization%molecular subtype
目的：检测血管内皮生长因子( VEGF)在乳腺癌中的表达情况,探讨其与乳腺癌临床病理参数及分子分型之间的关系。方法：采用免疫组织化学法检测乳腺癌标本中VEGF、雌激素受体、孕激素受体、人表皮生长因子受体2( Her-2)及增殖细胞核抗原67的表达情况。对Her-2(2+)的组织进行荧光原位杂交检测。根据雌激素受体、孕激素受体、Her-2及增殖细胞核抗原67的表达情况,将乳腺癌标本分为4个亚型,检测VEGF在各分子亚型中的表达情况。结果：VEGF在乳腺癌组织组中的阳性率显著高于良性病变组及癌旁组织组(P<0.01)。 VEGF在淋巴结转移者中的阳性率高于无淋巴结转移者(P <0.05)。VEGF的阳性率均随着组织学分级、临床分期的升高而升高(P<0.05~P<0.01)。在不同乳腺癌分子亚型中,Basal-like型乳腺癌组织中VEGF的阳性率高于Luminal A型(P<0.05)。结论：VEGF参与乳腺癌的发生、发展及浸润转移过程,有可能成为指导临床治疗的重要靶向指标之一。将乳腺癌中VEGF的表达情况与乳腺癌分子分型相互结合,有助于肿瘤恶性程度及预后的判断,有可能成为指导分子分型的又一重要指标。
目的：檢測血管內皮生長因子( VEGF)在乳腺癌中的錶達情況,探討其與乳腺癌臨床病理參數及分子分型之間的關繫。方法：採用免疫組織化學法檢測乳腺癌標本中VEGF、雌激素受體、孕激素受體、人錶皮生長因子受體2( Her-2)及增殖細胞覈抗原67的錶達情況。對Her-2(2+)的組織進行熒光原位雜交檢測。根據雌激素受體、孕激素受體、Her-2及增殖細胞覈抗原67的錶達情況,將乳腺癌標本分為4箇亞型,檢測VEGF在各分子亞型中的錶達情況。結果：VEGF在乳腺癌組織組中的暘性率顯著高于良性病變組及癌徬組織組(P<0.01)。 VEGF在淋巴結轉移者中的暘性率高于無淋巴結轉移者(P <0.05)。VEGF的暘性率均隨著組織學分級、臨床分期的升高而升高(P<0.05~P<0.01)。在不同乳腺癌分子亞型中,Basal-like型乳腺癌組織中VEGF的暘性率高于Luminal A型(P<0.05)。結論：VEGF參與乳腺癌的髮生、髮展及浸潤轉移過程,有可能成為指導臨床治療的重要靶嚮指標之一。將乳腺癌中VEGF的錶達情況與乳腺癌分子分型相互結閤,有助于腫瘤噁性程度及預後的判斷,有可能成為指導分子分型的又一重要指標。
목적：검측혈관내피생장인자( VEGF)재유선암중적표체정황,탐토기여유선암림상병리삼수급분자분형지간적관계。방법：채용면역조직화학법검측유선암표본중VEGF、자격소수체、잉격소수체、인표피생장인자수체2( Her-2)급증식세포핵항원67적표체정황。대Her-2(2+)적조직진행형광원위잡교검측。근거자격소수체、잉격소수체、Her-2급증식세포핵항원67적표체정황,장유선암표본분위4개아형,검측VEGF재각분자아형중적표체정황。결과：VEGF재유선암조직조중적양성솔현저고우량성병변조급암방조직조(P<0.01)。 VEGF재림파결전이자중적양성솔고우무림파결전이자(P <0.05)。VEGF적양성솔균수착조직학분급、림상분기적승고이승고(P<0.05~P<0.01)。재불동유선암분자아형중,Basal-like형유선암조직중VEGF적양성솔고우Luminal A형(P<0.05)。결론：VEGF삼여유선암적발생、발전급침윤전이과정,유가능성위지도림상치료적중요파향지표지일。장유선암중VEGF적표체정황여유선암분자분형상호결합,유조우종류악성정도급예후적판단,유가능성위지도분자분형적우일중요지표。
Objective:To detect the expression of vascuoar endothelial growth factor( VEGF) and investigate its relationship between clinicopathological features and molecular subtypes in breast cancer. Methods:The expressions of VEGF,estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2 ( Her-2 ) and nuclear associated antigen-67 in breast cancer were detected by immunohistochemical method. The Her-2 gene level was measured by fluorescence in situ hybridization. The breast cancers were divided into four molecular subtypes according to the expression levels of estrogen receptor,progesterone receptor,Her-2 and nuclear associated antigen-67,the expression of VEGF in different subtypes was measured. Results:The positive rate of VEGF expression in breast cancer tissue was significantly higher than that in benign lesion tissue and para-carcinoma tissue(P <0. 01). The positive rate of VEGF expression in breast cancer tissue with lymph node metastasis was significantly higher than that in breast cancer tissue without lymph node metastasis(P<0. 05). The positive rate of VEGF expression increased with the increasing of histological grade and clinical stage (P<0. 05 to P<0. 01). The positive rate of VEGF expression in type Basal-like was higher than that in type Luminal A(P<0. 05). Conclusions:VEGF involves the process of occurrence,development and metastasis of breast cancer,which maybe an important index in guiding clinical treatment. Combining the expression of VEGF with molecular subtype of breast cancer can contribute to judge the malignant degree and prognosis of tumor,which maybe another important index in guiding molecular subtype.
